NK Cell Therapy Pipeline 2025: Report Analyzes Over 140 Companies and 160 Therapies

Market research firm DelveInsight has published an analysis of the global NK cell therapy landscape. The report indicates that over 140 companies are actively engaged in developing more than 160 different NK cell therapeutic approaches.

The analysis covers the entire pipeline, from preclinical development to marketed products, examining drug mechanisms of action, clinical studies, approvals, and development activities including technology, collaborations, funding, and designations.

Key players in the field highlighted in the research include Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, and Athenex. Emerging therapies such as Bemarituzumab and L1 t-haNK are also identified based on their progression through clinical trials.

The report points to significant advancements by companies like ImmunityBio. In January 2026, the company announced sustained complete responses lasting up to 15 months in two patients treated with its CAR-NK cell therapy, reinforcing the potential of this approach for blood cancers. In September 2024, ImmunityBio initiated a clinical trial for a CD19-targeted CAR-NK cell therapy for lymphoma.

NK cell therapy utilizes the body's natural killer cells to target and destroy cancerous or infected cells. The technique is continually being refined to enhance its efficacy and expand its applications in precision medicine and immune system modulation.